» Articles » PMID: 19174764

Which Fecal Occult Blood Test is Best to Screen for Colorectal Cancer?

Overview
Specialty Gastroenterology
Date 2009 Jan 29
PMID 19174764
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Fecal immunochemical tests (FITs) for hemoglobin represent a major advance over guaiac-based fecal occult blood tests (GFOBTs) for colorectal cancer screening. FITs specifically detect human hemoglobin in stool samples, whereas GFOBTs only detect heme. Studies show that FITs increase the detection rates of cancer and advanced adenoma compared with early-generation GFOBTs, and do so without the unacceptably high number of colonoscopies that high-sensitivity GFOBTs generate. Also, FITs are simpler to use than GFOBTs, they improve rates of patient participation, and their cut-off points for positive versus negative tests can be modified. A large, Dutch, population-based, randomized controlled trial has compared the performance of a GFOBT and a FIT on an intention-to-screen basis. This study found that the FIT detected two-and-a-half times as many cancers and advanced adenomas as did the GFOBT, despite similar colonoscopy rates. The latest generation of FITs should replace traditional GFOBTs in two-step (test then colonoscopy) screening for colorectal cancer.

Citing Articles

Factors affecting the follow-up time after a positive result in the fecal occult blood test.

Cheng Y, Li Y PLoS One. 2021; 16(10):e0258130.

PMID: 34610043 PMC: 8491872. DOI: 10.1371/journal.pone.0258130.


Detection of advanced colorectal neoplasia and relative colonoscopy workloads using quantitative faecal immunochemical tests: an observational study exploring the effects of simultaneous adjustment of both sample number and test positivity threshold.

Young G, Woodman R, Symonds E BMJ Open Gastroenterol. 2020; 7(1).

PMID: 32994195 PMC: 7526287. DOI: 10.1136/bmjgast-2020-000517.


A Label-Free, Quantitative Fecal Hemoglobin Detection Platform for Colorectal Cancer Screening.

Soraya G, Nguyen T, Abeyrathne C, Huynh D, Chan J, Nguyen P Biosensors (Basel). 2017; 7(2).

PMID: 28475117 PMC: 5487963. DOI: 10.3390/bios7020019.


Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer.

Young G, Senore C, Mandel J, Allison J, Atkin W, Benamouzig R Cancer. 2016; 122(6):826-39.

PMID: 26828588 PMC: 5066737. DOI: 10.1002/cncr.29865.


Advances in Fecal Occult Blood Tests: the FIT revolution.

Young G, Symonds E, Allison J, Cole S, Fraser C, Halloran S Dig Dis Sci. 2014; 60(3):609-22.

PMID: 25492500 PMC: 4366567. DOI: 10.1007/s10620-014-3445-3.


References
1.
ALLISON J, Tekawa I, Ransom L, Adrain A . A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996; 334(3):155-9. DOI: 10.1056/NEJM199601183340304. View

2.
Cole S, Young G, Esterman A, Cadd B, Morcom J . A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen. 2003; 10(3):117-22. DOI: 10.1177/096914130301000304. View

3.
Smith A, Young G, Cole S, Bampton P . Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006; 107(9):2152-9. DOI: 10.1002/cncr.22230. View

4.
van Rossum L, van Rijn A, Laheij R, van Oijen M, Fockens P, van Krieken H . Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135(1):82-90. DOI: 10.1053/j.gastro.2008.03.040. View

5.
Nakajima M, Saito H, Soma Y, Sobue T, Tanaka M, Munakata A . Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: a case-control study. Br J Cancer. 2003; 89(1):23-8. PMC: 2394233. DOI: 10.1038/sj.bjc.6601002. View